Result of Retail Offer

Summary by AI BETAClose X

CRISM Therapeutics Corporation announced the successful completion and closure of its Retail Offer on 28 May 2026, which was significantly oversubscribed. The Directors have exercised their right to increase the Retail Offer size to £245,000 through the issuance of 2,450,000 Ordinary Shares, pending shareholder approval at the General Meeting on 15 June 2026. The proceeds from this offer, combined with the Placing announced on 26 May 2026, will provide crucial funding to secure grant funding, advance the Phase 2 clinical trial of irinotecan-ChemoSeed for glioblastoma, and support the development of docetaxel-ChemoSeed for prostate cancer.

Disclaimer*

UK 100

Latest directors dealings